Citigroup
MIRM icon

Citigroup’s Mirum Pharmaceuticals MIRM Stock Holding History

Citigroup’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3M Buy
165,136
+11,666
+8% +$1.17M 0.01% 1189
2026
Q1 		$14.2M Buy
153,470
+7,478
+5% +$703K 0.01% 1263
2025
Q4 		$11.5M Sell
145,992
-1,260
-0.9% -$90.4K 0.01% 1426
2025
Q3 		$10.8M Buy
147,252
+76,545
+108% +$4.87M ﹤0.01% 1434
2025
Q2 		$3.6M Sell
70,707
-63,014
-47% -$2.81M ﹤0.01% 2158
2025
Q1 		$6.02M Sell
133,721
-72
-0.1% -$3.39K ﹤0.01% 1739
2024
Q4 		$5.53M Sell
133,793
-17,700
-12% -$738K ﹤0.01% 1853
2024
Q3 		$5.91M Sell
151,493
-61,011
-29% -$2.43M ﹤0.01% 1716
2024
Q2 		$7.27M Sell
212,504
-158,547
-43% -$4.16M ﹤0.01% 1416
2024
Q1 		$9.32M Buy
371,051
+285,820
+335% +$7.86M 0.01% 1295
2023
Q4 		$2.52M Buy
85,231
+26,508
+45% +$802K ﹤0.01% 2049
2023
Q3 		$1.86M Buy
58,723
+17,917
+44% +$491K ﹤0.01% 2042
2023
Q2 		$1.06M Sell
40,806
-28,571
-41% -$760K ﹤0.01% 2808
2023
Q1 		$1.67M Sell
69,377
-98,196
-59% -$2.24M ﹤0.01% 2145
2022
Q4 		$3.27M Buy
167,573
+29,407
+21% +$581K ﹤0.01% 1718
2022
Q3 		$2.9M Buy
138,166
+136,395
+7,702% +$3.28M ﹤0.01% 1889
2022
Q2 		$34K Buy
1,771
+966
+120% +$22.8K ﹤0.01% 4717
2022
Q1 		$18K Sell
805
-1,039
-56% -$21.2K ﹤0.01% 5213
2021
Q4 		$29K Buy
1,844
+1,433
+349% +$22.3K ﹤0.01% 5282
2021
Q3 		$8K Buy
411
+240
+140% +$3.9K ﹤0.01% 5523
2021
Q2 		$3K Sell
171
-228
-57% -$4.09K ﹤0.01% 5923
2021
Q1 		$8K Sell
399
-672
-63% -$12.9K ﹤0.01% 5762
2020
Q4 		$19K Buy
1,071
+821
+328% +$16.1K ﹤0.01% 6680
2020
Q3 		$5K Sell
250
-498
-67% -$10.7K ﹤0.01% 7026
2020
Q2 		$15K Buy
748
+154
+26% +$2.57K ﹤0.01% 6816
2020
Q1 		$8K Buy
594
+54
+10% +$886 ﹤0.01% 7125
2019
Q4 		$13K Buy
540
+421
+354% +$4.49K ﹤0.01% 7109
2019
Q3 		$2K Buy
+119
New +$1.46K ﹤0.01% 7543

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's MIRM Position: Q2 2026 in Review

Citigroup increased its Mirum Pharmaceuticals (MIRM) stake by 7.6% in Q2 2026, buying an estimated $1.17M and bringing the position to 165,136 shares worth $19.3M. The position accounts for 0.01% of the portfolio, ranked #1189.

Citigroup first reported a position in MIRM in Q3 2019 and has held it in 28 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Citigroup held 165,136 shares of Mirum Pharmaceuticals worth $19.3M as of Q2 2026.
  • Citigroup bought 11,666 Mirum Pharmaceuticals shares in Q2 2026, an estimated $1.17M.
  • Mirum Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q2 2026, its #1189 holding.
  • Citigroup first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.